Effect of long-term treatment with galantamine on weight of patients with Alzheimer’s dementia

Droogsma, E.; Asselt, D.Z.B. van; Steijn, J. H. M. Van; Schuur, T.; Huinink, E.

doi:10.1007/s12603-012-0428-y

Cited by 7 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results from the MNA questionnaire are in agreement with a recent study of the MNA in Dutch AD patients that showed that outpatients of a memory clinic showed no protein-energy malnutrition, while a subgroup (14%) showed higher risk on such malnutrition [39]. In addition, the findings on nourishment status in the currently studied AD patients are in line with literature data, which suggest a positive association between prevalence of (risk of) protein/energy malnutrition and stage of AD [11][12][13][14]39].…”

Section: Discussionsupporting

confidence: 92%

Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls

Rikkert

Verhey

Sijben

et al. 2014

JAD

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls

Rikkert

Verhey

Sijben

et al. 2014

JAD

View full text Add to dashboard Cite

show abstract

“…However, it remains unclear how AChEIs affect nutritional status (eg, weight loss, malnutrition), a central factor that significantly influences disease progression. It has been reported that AChEIs may accelerate weight loss by increasing cholinergic activity in the gastrointestinal system and causing nausea, vomiting and diarrhoea, particularly at the beginning of treatment 14. However, others have proposed that since AChEIs improve the cognitive status, with good cognitive status being essential for the prevention of malnutrition, it is possible that an improvement in nutritional status could be observed 15.…”

Section: Introductionmentioning

confidence: 99%

Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis

Soysal

Işık

Stubbs

et al. 2016

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

We conducted a systematic review and meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutritional status and weight across observational and interventional studies. Two authors searched major electronic databases from inception until 10/14/2015 for longitudinal, open-label and randomised double-blind placebo controlled (randomised controlled trials (RCTs)) studies of AChEIs in patients with dementia reporting nutritional status outcome data. Out of 3551 initial hits, 25 studies (12 open-label trials, 9 RCTs and 4 longitudinal studies) including 10 792 patients with dementia were meta-analysed. In longitudinal studies (median follow-up 6 months), a significant cumulative incidence of weight loss between baseline and follow-up evaluation was observed (studies=2; 5%; 95% CI 1% to 34%, p<0.0001; I=95%). These findings were confirmed in open-label trials (6%; 95% CI 4% to 7%, p<0.0001; I=78%). In 9 RCTs (median follow-up 5 months), those taking AChEIs more frequently experienced weight loss than participants taking placebo (OR=2.18; 95% CI 1.50 to 3.17, p<0.0001; I=29%). AChEIs therapy contributes to weight loss in patients with dementia, with a 2-fold increased risk observed in the meta-analysis of RCTs. Clinicians should carefully consider the benefit and risk of prescribing AChEIs. Nutritional status should be routinely evaluated in patients with dementia treated with AChEIs.

show abstract

“…One study from France of 486 individuals treated with cholinesterase inhibitors found that 21% of participants experienced a weight loss of 4% or more, but there was no meaningful control group for comparison. Another observational study in the Netherlands found no difference in weight loss between galantamine and donepezil, although there was no placebo or control group for comparison. This is consistent with data from a metaanalysis revealing a similar side‐effect profile of donepezil, galantamine, and rivastigmine …”

Section: Discussionmentioning

confidence: 99%

Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System

Sheffrin

Miao

Boscardin

et al. 2015

J American Geriatrics Society

View full text Add to dashboard Cite

Background/Objectives Inconsistent data from randomized trials suggest cholinesterase inhibitors may cause weight loss. We sought to determine if the initiation of cholinesterase inhibitors is associated with significant weight loss in a real-word clinical setting. Design Retrospective cohort study from 2007-2010, comparing weight loss in patients with dementia newly prescribed cholinesterase inhibitors and patients newly prescribed other chronic medications Setting National Veterans Affairs (VA) data Participants Patients 65 years or older with a diagnosis of dementia who received a new prescription for a cholinesterase inhibitor or other new other chronic medication. Measurements The primary outcome was time to 10 pound weight loss over 12 months. We used propensity score matching patients to control for the likelihood of receiving a cholinesterase inhibitor based on baseline characteristics. Data were analyzed in a priori defined subgroups by age, comorbid burden, and initial weight. Results Of 6,504 patients that met study criteria, 1188 patients started on cholinesterase inhibitors were matched to 2189 patients started on other medications. The propensity-matched cohorts were well balanced on baseline covariates. Patients initiated on cholinesterase inhibitors had a higher risk of weight loss compared to matched controls at 12 months, HR 1.23 (95% CI 1.07 - 1.41). At twelve months, 29.3% of patients on cholinesterase inhibitors had experienced weight loss compared to 22.8% of non-users, corresponding to a number needed to harm of 21.2 (95% CI 12.5 – 71.4) over one year. There were no significant differences across subgroups. Conclusion Patients with dementia started on cholinesterase inhibitors had a higher risk of clinically significant weight loss over a 12-month period compared to matched controls. These results are consistent with the available data from randomized controlled trials. Clinicians should consider the risk of weight loss when prescribing cholinesterase inhibitors.

show abstract

Effect of long-term treatment with galantamine on weight of patients with Alzheimer’s dementia

Cited by 7 publications

References 21 publications

Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls

Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls

Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis

Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System

Contact Info

Product

Resources

About